Abstract
AbstractOverview of:Butler CC, Hobbs FDR, Gbinigie OA,et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.Lancet2023;401:281–93.
Subject
Pharmacology (medical),General Medicine
Reference5 articles.
1. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
2. Two new oral antivirals for covid-19: ▼molnupiravir and ▼nirmatrelvir plus ritonavir
3. NHS England . Interim clinical commissioning policy: treatments for non-hospitalised patients with COVID-19 [online]. 2022. Available: https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-neutralising-monoclonal-antibodies-or-antivirals-for-non-hospitalised-patients-with-covid-19/ [Accessed 3 Apr 2023].
4. National Institute for Health and Care Excellence . Molnupiravir, remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (ID6261). 2023. Available: https://www.nice.org.uk/guidance/indevelopment/gid-ta11297 [Accessed 3 Apr 2023].
5. European Medicines Agency . Refusal of the marketing authorisation for Lagevrio (molnupiravir). 2023. Available: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/lagevrio [Accessed 3 Apr 2023].